TY - JOUR AU - Cuzick, J. PY - 2003 DA - 2003// TI - Overview of the main outcomes in breast cancer prevention trials JO - Lancet VL - 361 UR - https://doi.org/10.1016/S0140-6736(03)12342-2 DO - 10.1016/S0140-6736(03)12342-2 ID - Cuzick2003 ER - TY - JOUR AU - McKay, A. AU - Martin, W. AU - Latosinsky, S. PY - 2005 DA - 2005// TI - How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide JO - Breast Cancer Res Treat VL - 94 UR - https://doi.org/10.1007/s10549-005-6932-6 DO - 10.1007/s10549-005-6932-6 ID - McKay2005 ER - TY - JOUR AU - Phillips, K. PY - 2006 DA - 2006// TI - Risk-Reducing Surgery, Screening and Chemoprevention Practices Of BRCA1 And BRCA2 Mutation Carriers: A Prospective Cohort Study JO - Clin Genet. VL - 70 UR - https://doi.org/10.1111/j.1399-0004.2006.00665.x DO - 10.1111/j.1399-0004.2006.00665.x ID - Phillips2006 ER - TY - JOUR AU - Savage, L. PY - 2007 DA - 2007// TI - Researchers wonder why high-risk women are not taking chemoprevention drugs JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djm032 DO - 10.1093/jnci/djm032 ID - Savage2007 ER - TY - JOUR AU - Metcalfe, K. PY - 2005 DA - 2005// TI - The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation JO - Familial Cancer VL - 4 UR - https://doi.org/10.1007/s10689-005-4215-3 DO - 10.1007/s10689-005-4215-3 ID - Metcalfe2005 ER - TY - JOUR AU - Veronesi, U. PY - 2007 DA - 2007// TI - Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djk154 DO - 10.1093/jnci/djk154 ID - Veronesi2007 ER - TY - JOUR AU - Powles, T. PY - 2007 DA - 2007// TI - Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djk050 DO - 10.1093/jnci/djk050 ID - Powles2007 ER - TY - JOUR AU - Fisher, B. PY - 1998 DA - 1998// TI - Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study JO - J Natl Cancer Inst VL - 90 UR - https://doi.org/10.1093/jnci/90.18.1371 DO - 10.1093/jnci/90.18.1371 ID - Fisher1998 ER - TY - JOUR AU - Cuzick, J. PY - 2007 DA - 2007// TI - Long-term results of tamoxifen prophylaxis for breast cancer – 96 month follow-up of the randomized IBIS I-study JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djk049 DO - 10.1093/jnci/djk049 ID - Cuzick2007 ER - TY - JOUR AU - Veronesi, U. AU - Maisonneuve, P. AU - Decensi, A. PY - 2007 DA - 2007// TI - Tamoxifen: An enduring star JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djk072 DO - 10.1093/jnci/djk072 ID - Veronesi2007 ER - TY - JOUR AU - Nelson, H. PY - 2005 DA - 2005// TI - Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force JO - Ann Intern Med VL - 143 UR - https://doi.org/10.7326/0003-4819-143-5-200509060-00012 DO - 10.7326/0003-4819-143-5-200509060-00012 ID - Nelson2005 ER - TY - JOUR AU - Vogel, V. PY - 2006 DA - 2006// TI - Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene [STAR] P-2 trial JO - JAMA VL - 295 UR - https://doi.org/10.1001/jama.295.23.joc60074 DO - 10.1001/jama.295.23.joc60074 ID - Vogel2006 ER - TY - JOUR AU - King, M. PY - 2001 DA - 2001// TI - Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial JO - JAMA VL - 286 UR - https://doi.org/10.1001/jama.286.18.2251 DO - 10.1001/jama.286.18.2251 ID - King2001 ER - TY - JOUR AU - Keating, N. PY - 2008 DA - 2008// TI - Physicians' experiences with BRCA1/2 testing in community settings JO - Journal of Clinical Oncology VL - 26 UR - https://doi.org/10.1200/JCO.2008.17.8053 DO - 10.1200/JCO.2008.17.8053 ID - Keating2008 ER - TY - JOUR AU - Bober, S. PY - 2004 DA - 2004// TI - Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.192 DO - 10.1200/JCO.2004.05.192 ID - Bober2004 ER - TY - JOUR AU - Cyrus-David, M. AU - Strom, S. PY - 2001 DA - 2001// TI - Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse groups of women with elevated risk for breast cancer JO - Psychooncology VL - 10 UR - https://doi.org/10.1002/pon.547 DO - 10.1002/pon.547 ID - Cyrus-David2001 ER - TY - JOUR AU - Slevin, M. PY - 1990 DA - 1990// TI - Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public JO - BMJ VL - 300 UR - https://doi.org/10.1136/bmj.300.6737.1458 DO - 10.1136/bmj.300.6737.1458 ID - Slevin1990 ER - TY - JOUR AU - O'Connor, A. PY - 1989 DA - 1989// TI - Effects of framing and level of probability on patients' preferences for cancer chemotherapy JO - J Clin Epidemiol VL - 42 UR - https://doi.org/10.1016/0895-4356(89)90085-1 DO - 10.1016/0895-4356(89)90085-1 ID - O'Connor1989 ER - TY - JOUR AU - Peshkin, B. PY - 2003 DA - 2003// TI - Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.02.107 DO - 10.1200/JCO.2003.02.107 ID - Peshkin2003 ER - TY - JOUR AU - Kaplan, C. PY - 2005 DA - 2005// TI - Factors affecting breast cancer risk reduction practices among California physicians JO - Prev Med VL - 41 UR - https://doi.org/10.1016/j.ypmed.2004.09.041 DO - 10.1016/j.ypmed.2004.09.041 ID - Kaplan2005 ER - TY - CHAP AU - Liamputtong Rice, P. AU - Ezzy, D. PY - 1999 DA - 1999// BT - Qualitative Research Methods: A Health Focus PB - Oxford University Press CY - Melbourne ID - Liamputtong Rice1999 ER - TY - JOUR AU - Butow, P. AU - Lobb, E. PY - 2004 DA - 2004// TI - Analyzing the process and content of genetic counseling in familial breast cancer consultations JO - J Genetic Counselling VL - 13 UR - https://doi.org/10.1023/B:JOGC.0000044201.73103.4f DO - 10.1023/B:JOGC.0000044201.73103.4f ID - Butow2004 ER - TY - JOUR AU - Antill, Y. AU - Shanahan, M. AU - Phillips, K. PY - 2005 DA - 2005// TI - The integrated multidisciplinary clinic: A new model for the ongoing management of women at high genetic risk for breast and ovarian cancer JO - Cancer Forum VL - 29 ID - Antill2005 ER - TY - STD TI - Familial aspects of cancer: a guide to clinical practice Biotext, NHMRC: Canberra; 1999. ID - ref24 ER - TY - JOUR AU - Goldberg, K. PY - 2007 DA - 2007// TI - Specter seeks NCI explanation of delay in P-4 breast cancer prevention trial JO - The Cancer Letter VL - 33 ID - Goldberg2007 ER - TY - STD TI - Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer2007. [http://www.kconfab.org/Index.shtml] UR - http://www.kconfab.org/Index.shtml ID - ref26 ER - TY - JOUR AU - Li, W. PY - 2007 DA - 2007// TI - A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation JO - Oncogene VL - 26 UR - https://doi.org/10.1038/sj.onc.1210527 DO - 10.1038/sj.onc.1210527 ID - Li2007 ER - TY - JOUR AU - Daidone, M. PY - 2002 DA - 2002// TI - Estrogen receptor-beta expression in hereditary breast cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.99.116 DO - 10.1200/JCO.2002.99.116 ID - Daidone2002 ER - TY - JOUR AU - Poole, S. AU - Dooley, M. PY - 2004 DA - 2004// TI - Off-label prescribing in oncology JO - Support Care Cancer VL - 12 UR - https://doi.org/10.1007/s00520-004-0593-6 DO - 10.1007/s00520-004-0593-6 ID - Poole2004 ER - TY - JOUR AU - Gazarian, M. PY - 2006 DA - 2006// TI - Off-label use of medicines: consensus recommendations for evaluating appropriateness JO - MJA VL - 185 ID - Gazarian2006 ER - TY - JOUR AU - Kinsinger, L. PY - 2002 DA - 2002// TI - Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force JO - Ann Intern Med VL - 137 UR - https://doi.org/10.7326/0003-4819-137-1-200207020-00017 DO - 10.7326/0003-4819-137-1-200207020-00017 ID - Kinsinger2002 ER - TY - JOUR AU - Levine, M. PY - 2001 DA - 2001// TI - Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer JO - CMAJ VL - 164 ID - Levine2001 ER - TY - JOUR AU - Chlebowski, R. PY - 2002 DA - 2002// TI - American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.06.029 DO - 10.1200/JCO.2002.06.029 ID - Chlebowski2002 ER - TY - JOUR PY - 2002 DA - 2002// TI - First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial JO - Lancet VL - 360 UR - https://doi.org/10.1016/S0140-6736(02)09962-2 DO - 10.1016/S0140-6736(02)09962-2 ID - ref34 ER - TY - JOUR AU - Metcalfe, K. PY - 2007 DA - 2007// TI - Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation JO - Clin Genet VL - 72 UR - https://doi.org/10.1111/j.1399-0004.2007.00859.x DO - 10.1111/j.1399-0004.2007.00859.x ID - Metcalfe2007 ER -